PDSB

PDS Biotechnology Corporation

NasdaqCMUSDEQUITY DELAYED

0.22

▲ 0.01 (4.55%)

MARKET · —

Price

Open

0.22

Prev close

0.21

Day high

0.24

Day low

0.21

Volume

2.89M

Market cap

—

P/E (TTM)

—

52W range

0.20 – 1.55

Trailing performance

Price return · vs SPY

Returnvs SPY

-5.19% -3.8%

-68.76% -72.5%

-81.12% -84.2%

-66.20% -77.3%

YTD

-71.56% -83.8%

-81.28% -101.3%

-96.48% -170.7%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

0.28

-20.64% from price

SMA 20

0.49

-55.64% from price

SMA 50

0.70

-68.92% from price

SMA 100

0.89

-75.55% from price

SMA 200

0.85

-74.13% from price

EMA 12

0.33

-34.32% from price

EMA 26

0.49

-55.54% from price

EMA 50

0.64

-65.98% from price

RSI (14)

19.5

Oversold

MACD (12,26,9)

-0.16

Hist -0.03

ATR (14)

0.07

32.13% of price

Realised vol 30D

301.2%

Annualised

Bollinger upper

0.98

20, 2σ

Bollinger lower

0.00

20, 2σ

50 / 200 cross

Death

0.70 vs 0.85

Trend bias

Below 200

-74.13%

Risk profile

Daily returns · 1Y window

Beta vs SPY

2.93

More volatile than market

Correlation to SPY

0.32

Loosely linked

Realised vol 30D

301.2%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-85.9%

Peak to trough

Max drawdown 5Y

-98.8%

Peak to trough

ATR 14

0.07

32.13% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 0.22

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

PDSB · links out to the publisher

PDS Biotechnology: Q2 Earnings Snapshot Associated Press · 9d ago PDS Biotech Reports Second Quarter 2026 Financial Results GlobeNewswire · 9d ago PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 GlobeNewswire · 11d ago Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher Zacks · 73d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.